Nxstage Medical Beats Up on Analysts Yet Again

Nxstage Medical (NAS: NXTM) reported earnings on May 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Nxstage Medical met expectations on revenues and exceeded expectations on earnings per share.

Compared with the prior-year quarter, revenue improved and GAAP loss per share shrank.


Margins improved across the board.

Revenue details
Nxstage Medical booked revenue of $57.0 million. The 11 analysts polled by S&P Capital IQ wanted to see revenue of $56.4 million on the same basis. GAAP reported sales were 13% higher than the prior-year quarter's $50.6 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.09. The 10 earnings estimates compiled by S&P Capital IQ averaged -$0.10 per share. GAAP EPS were -$0.09 for Q1 compared to -$0.11 per share for the prior-year quarter.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 37.4%, 170 basis points better than the prior-year quarter. Operating margin was -6.4%, 280 basis points better than the prior-year quarter. Net margin was -9.0%, 290 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $58.8 million. On the bottom line, the average EPS estimate is -$0.09.

Next year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.26.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 142 members out of 174 rating the stock outperform, and 32 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 41 give Nxstage Medical a green thumbs-up, and 10 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $26.00.

Over the decades, small-cap stocks like Nxstage Medical have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story